Media release
From:
JAMA
Severity and Long-Term Mortality of COVID-19, Influenza, and RSV
About The Study: This cohort study showed that, during the 2022 to 2023 season, infection with SARS-CoV-2 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV), whereas differences were less pronounced during the 2023 to 2024 season. During both seasons, RSV remained a milder illness, whereas COVID-19 was associated with higher long-term mortality. Vaccination attenuated differences in disease severity and long-term mortality.
Attachments
Note: Not all attachments are visible to the general public.
Research URLs will go live after the embargo ends.
Research
JAMA, Web page
The URL will go live after the embargo ends
Journal/
conference:
JAMA Internal Medicine
Organisation/s:
Veterans Affairs Portland Health Care System, USA
Funder:
This study was supported by the
US Department of Veterans Affairs Cooperative
Studies Program (CSP) and funded in part by the
Department of Health and Human Services,
Biomedical Advanced Research and Development
Authority (interagency agreement No. AAI21050),
and US Food and Drug Administration (interagency
agreement No. 75F40121S30013).